steroidnpeptides weighs loss against preservation
Protecting weight during chemotherapy, reducing deep abdominal fat, measuring hormones: three ambitions inside a performance-sounding name.
Weight, tissues and the ambitions of peptide research.
Ipamorelin after chemotherapy
A ferret makes an awkward mascot for steroidnpeptides. Yet the 2024 experiment with ipamorelin and cisplatin pursued a compelling ambition: helping an animal retain weight during chemotherapy.
In those ferrets, ipamorelin inhibited body-weight loss by approximately 24% on the last day of the delayed phase, 48 to 72 hours after cisplatin. It had no anti-emetic effect in either the acute or delayed phase: vomiting continued. The authors also tested anamorelin, a different compound, and the anti-emetic finding in the paper's title belongs to that other agent.
That is a modest, oddly specific success. I like its ambition. Keeping weight on an animal under this kind of stress is a worthwhile problem in its own right; turning the result into a claim about a leaner human body would discard the very question the experiment answered.
Less fat, more lean mass
Tesamorelin points in another direction. In five pooled randomised trials in HIV-associated lipodystrophy, deep abdominal fat decreased, trunk fat decreased and lean body mass increased. The changes concern different tissues. A bathroom scale cannot tell that whole story.
Visceral adipose tissue is the fat around the abdominal organs. The pooled mean difference for that tissue was -27.71 square centimetres, with a 95% confidence interval of -38.37 to -17.06. These were adults with HIV-associated fat redistribution, a clinical problem quite specific enough to deserve its own name and its own evidence.
Tesamorelin earns some respect from me for reaching a measurable clinical outcome. Its U.S. approval covers excess abdominal fat in adults with HIV-associated lipodystrophy. General fat loss and anti-ageing uses remain outside that approval. The tesamorelin page follows the compartments separately, including the fat that returned after treatment stopped.
CJC-1295 blood studies
CJC-1295 supplies the tempting middle step: a conspicuous rise in hormones. In healthy-adult pharmacology studies, mean growth hormone rose two- to ten-fold for six days or more, while IGF-1 rose one-and-a-half- to three-fold for nine to eleven days after a single administration.
The chemical achievement impresses me. The long-acting peptide attaches to albumin in blood and remains active far longer than the natural signal it imitates. The published studies in healthy adults followed hormone concentrations and serum proteins; they leave a body-composition trial in healthy trained adults still to be done.
CJC-1295 gets a page about that achievement and its unfinished clinical history. Ipamorelin gets a different one, starting with the very ordinary business of eating after surgery. The growth hormone comparison brings the actual outcomes together.
Name and sport
The little “n” in steroidnpeptides joins categories that often arrive in the same conversation. This site follows ipamorelin, CJC-1295 and tesamorelin. Anabolic-androgenic steroids are a controlled-substance class, and there are no steroid regimens, sourcing instructions or combinations for use here. None of these peptides is presented as a substitute or partner for anabolic steroids.
All three peptides are prohibited in sport at all times under category S2 of the World Anti-Doping Agency list. CJC-1295 has also been identified by mass spectrometry in an unknown preparation seized in an anti-doping context. A sporting prohibition and a demonstrated performance benefit answer separate questions.
The tissue that changes, and the purpose of changing it, are my preoccupations here. The ferret experiment is an excellent reminder that a desirable result can mean losing less.